SGLT-2 Inhibition Using Dapagliflozin During and After Physical Exercise - Effects on Glycemic Variability, Hormonal Regulators of Glucose Homeostasis and Ketone Body in Type 1 Diabetes - a Randomized, Placebo-controlled, Open-label, Cross-over Intervention Study
Latest Information Update: 04 Sep 2023
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
Most Recent Events
- 30 Aug 2023 Status changed from recruiting to completed.
- 07 Nov 2022 Planned End Date changed from 30 Nov 2022 to 30 Mar 2023.
- 07 Nov 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Mar 2023.